Bauer P. Multistage testing with adaptive designs. Biometrie und Informatik in Medizin und Biologie. 1989;20(4):130– 48.
Bauer P, Kohne K (1994) Evaluation of Experiments with Adaptive Interim Analyses. Biometrics 50:1029. Correction: Biometrics 1996; 52:380.
Bauer P, Röhmel J (1995) An adaptive method for establishing a dose-response relationship. Statistics in Medicine 14:1595–1607
Article CAS PubMed Google Scholar
Bauer P, Bretz F, Dragalin V, et al. (2015) Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. Statistics in Medicine 35:325–347
Article PubMed PubMed Central Google Scholar
Chang M, Balser J. Adaptive design - recent Advancement in clinical trials. J Bioanal Biostat 2016;1(1): 14
U.S. Food and Drug Administration (2019). Guidance for industry, Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry
Bhatt DL, Mehta C (2016) Adaptive designs for clinical trials. N Engl J Med 375:65–74
Kunz CU, Friede T, Parsons N, et al. (2015) A comparison of methods for treatment selection in Seamless Phase II/III clinical trials incorporating information on short-term endpoints. Journal of Biopharmaceutical Statistics 25:170–189
Article PubMed PubMed Central Google Scholar
Maca J, Bhattacharya S, Dragalin V, et al. (2006) Adaptive seamless phase II/III Designs—Background, operational aspects, and examples. Drug Information J 40:463–473
Stallard N, Todd S (2010) Seamless phase II/III designs. Stat Methods Med Res 20:623–634
Coffey CS, Levin B, Clark C, et al. (2012) Overview, hurdles, and future work in adaptive designs: perspectives from a National institutes of Health-funded workshop. Clinical Trials 9:671–680
Wang S, O’Neill RT, Hung HMJ (2007) Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227–244
Quan H, Zhou D, Mancini P, et al. (2012) Adaptive patient Population Selection Design in clinical trials. Statistics in Biopharmaceutical Research 4:86–99
Ondra T, Jobjörnsson S, Beckman RA, et al. (2017) Optimized adaptive enrichment designs. Stat Methods Med Res 28:2096–2111
Article PubMed PubMed Central Google Scholar
Johnston SE, Lipkovich I, Dmitrienko A, et al. (2022) A two-stage adaptive clinical trial design with data‐driven subgroup identification at interim analysis. Pharmaceutical Statistics 21:1090–1108
Article PubMed PubMed Central Google Scholar
Frieri R, Rosenberger WF, Flournoy N, et al. (2022) Design considerations for two-stage Enrichment clinical trials. Biometrics 79:2565–2576
Wu J, Li Y (2023) Group sequential multi-arm multi-stage survival trial design with treatment selection. Journal of Biopharmaceutical Statistics 1–16
Jin M, Zhang P (2021) A seamless adaptive 2-in-1 design expanding a phase 2 trial for treatment or dose selection into a phase 3 trial. Statistics in Biopharmaceutical Research 14:334–341
Karrison TG, Huo D, Chappell R (2003) A group sequential, response-adaptive design for randomized clinical trials. Controlled Clinical Trials 24:506–522
Wang L, Cui L (2007) Seamless phase II/III combination study through response adaptive randomization. Journal of Biopharmaceutical Statistics 17:1177–1187
Liu Z, Ma X, Wang Z (2020) Subgroup-adaptive randomization for subgroup confirmation in clinical trials. Biometrical J 63:616–631
Edwards JM, Walters SJ, Kunz C, et al. (2020) A systematic review of the “promising zone” design. Trials. https://doi.org/10.1186/s13063-020-04931-w
Xu H, Liu Y, Beckman RA (2023) Adaptive endpoints selection with application in Rare Disease. Statistics in Biopharmaceutical Research 16:55–63
Sinha AK, Moye L III, Piller LB, et al. (2023) Simultaneous population enrichment and endpoint selection in phase 3 randomized controlled trials: An adaptive group sequential design with two binary alternative primary endpoints. Communications in Statistics - Theory and Methods 1–14
Wu J, Li Y, Zhu L (2023) Group sequential multi-arm multi‐stage trial design with treatment selection. Statistics in Medicine 42:1480–1491
Khan JN, Kimani PK, Glimm E, et al. (2022) Adjusting for treatment selection in phase II/III clinical trials with time to event data. Statistics in Medicine 42:146–163
Article PubMed PubMed Central Google Scholar
Wason J, Stallard N, Bowden J, et al. (2016) A multi-stage drop-the-losers design for multi-arm clinical trials. Stat Methods Med Res 26:508–524
Article PubMed PubMed Central Google Scholar
Noronha V, Patil VM, Menon NS, et al. (2022) Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial. Esophagus 19:670–682
Article CAS PubMed Google Scholar
Tomizawa D, Tanaka S, Hasegawa D, et al. (2018) Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children’s Cancer Group Multi-center Seamless Phase II–III randomized trial (JPLSG AML-12). Japanese Journal of Clinical Oncology 48:587–593
Martín M, Chan A, Dirix L, et al (2017) A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4). Annals of Oncology 28:313–320
Placzek M, Friede T (2019) A conditional error function approach for adaptive enrichment designs with continuous endpoints. Statistics in Medicine 38:3105–3122
Lehmacher W, Wassmer G (1999) Adaptive sample size calculations in Group Sequential trials. Biometrics 55:1286–1290
Article CAS PubMed Google Scholar
Cui L, Hung HMJ, Wang S (1999) Modification of sample size in Group Sequential clinical trials. Biometrics 55:853–857
Article CAS PubMed Google Scholar
Todd S, Stallard N (2005) A New Clinical Trial Design combining phases 2 and 3: sequential designs with treatment selection and a change of Endpoint. Drug Information J 39:109–118
Royston P, Parmar MKB, Qian W (2003) Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Statistics in Medicine 22:2239–2256
Jenkins M, Stone A, Jennison C (2010) An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†. Pharmaceutical Statistics 10:347–356
Wang S, James Hung HM, O’Neill RT (2009) Adaptive patient enrichment designs in therapeutic trials. Biometrical J 51:358–374
Graf AC, Posch M, Koenig F (2014) Adaptive designs for subpopulation analysis optimizing utility functions. Biometrical J 57:76–89
Wassmer G, Dragalin V (2014) Designing issues in Confirmatory Adaptive Population Enrichment trials. Journal of Biopharmaceutical Statistics 25:651–669
Mehta C, Gao P, Bhatt DL, et al. (2009) Optimizing Trial Design. Circulation 119:597–605
Mehta CR, Gao P (2011) Population Enrichment designs: Case Study of a large multinational trial. Journal of Biopharmaceutical Statistics 21:831–845
Friede T, Parsons N, Stallard N (2012) A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31:4309–4320
留言 (0)